Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Systemic second- and third-line therapies for malignant pleural mesothelioma (MPM) result in a median progression-free survival (mPFS) of

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2020-04, Vol.31 (4), p.495-500
Hauptverfasser:	Metaxas, Y., Früh, M., Eboulet, E.I., Grosso, F., Pless, M., Zucali, P.A., Ceresoli, G.L., Mark, M., Schneider, M., Maconi, A., Perrino, M., Biaggi-Rudolf, C., Froesch, P., Schmid, S., Waibel, C., Appenzeller, C., Rauch, D., von Moos, R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Carbolines Heterocyclic Compounds, 4 or More Rings Humans Italy lurbinectedin mesothelioma Mesothelioma - drug therapy Mesothelioma, Malignant Palliative Care phase II trial Pleural Neoplasms - drug therapy Switzerland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Systemic second- and third-line therapies for malignant pleural mesothelioma (MPM) result in a median progression-free survival (mPFS) of
ISSN:	0923-7534 1569-8041
DOI:	10.1016/j.annonc.2019.12.009